Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP4 | P49662 | 1/20 | 0.38 |
| ▸ | CASP5 | P51878 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368445 | 0.98 | HTR2C (0.47) | HTR2CHTR2BHRH1USP2SMN1; SMN2 | |
| SCHEMBL44952 | 0.93 | — | — | |
| SCHEMBL3859847 | 0.83 | — | — | |
| SCHEMBL4977848 | 0.80 | HTR2C (0.39) | HTR2CHTR2BHRH1USP2SMN1; SMN2 | |
| SCHEMBL1481847 | 0.78 | USP2 (0.48) | HTR2CHTR2BHRH1USP2SMN1; SMN2 | |
| SCHEMBL28691107 | 0.78 | USP2 (0.48) | HTR2CHTR2BHRH1USP2SMN1; SMN2 | |
| SCHEMBL1481868 | 0.75 | ALDH1A1 (0.46) | HTR2CHTR2BHRH1USP2SMN1; SMN2 | |
| SCHEMBL28013101 | 0.74 | HRH1 (0.46) | HTR2CHTR2BHRH1USP2SMN1; SMN2 | |
| SCHEMBL5037562 | 0.74 | INMT (0.40) | HRH1USP2TDP1CHKAALDH1A1 | |
| SCHEMBL1826475 | 0.74 | INMT (0.40) | HRH1USP2TDP1CHKAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138018-A1 | TREATMENT OF GEMIN5-MEDIATED DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-06-27 | — | — | WO | claimed |
| CN-112469707-B | Preventive or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2024-06-21 | — | — | CN | claimed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | claimed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | claimed |
| WO-2024017227-A1 | SUBSTITUTED FUSED RING CANNABINOID RECEPTOR COMPOUND AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-01-25 | — | — | WO | claimed |
| EP-3623369-B1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | claimed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | claimed |
| EP-1201649-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | claimed |
| EP-1201660-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | claimed |
| US-6852719-B2 | Dietetics; antidiabetic agents; antiinflammatory agents | PFIZER INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | claimed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | claimed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | claimed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | HTR2C 4328/4885HTR2B 3963/4885HRH1 2943/4885 |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | HTR2C 266/4885HTR2B 490/4885HRH1 1237/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | HTR2C 222/4885HTR2B 348/4885HRH1 1083/4885 |
| US-20040014741-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | HTR2C 821/4885HTR2B 1070/4885HRH1 1038/4885 |
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | HTR2C 25/4885HTR2B 88/4885HRH1 214/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | HTR2C 496/4885HTR2B 1477/4885HRH1 1854/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | HTR2C 801/4885HTR2B 1021/4885HRH1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.